Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans
about
Regulation of glucose homeostasis by GLP-1The Use of Rat and Mouse Models in Bariatric Surgery ExperimentsIs GLP-1 a hormone: Whether and When?Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgeryCan medical therapy mimic the clinical efficacy or physiological effects of bariatric surgery?Do we really know why diabetes remits after gastric bypass surgery?Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseaseRemodeling of the residual gastric mucosa after roux-en-y gastric bypass or vertical sleeve gastrectomy in diet-induced obese ratsGlucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic SuccessesA gut feeling to cure diabetes: potential mechanisms of diabetes remission after bariatric surgeryThe role of gut adaptation in the potent effects of multiple bariatric surgeries on obesity and diabetesGut-Brain Cross-Talk in Metabolic Control.Altered islet function and insulin clearance cause hyperinsulinemia in gastric bypass patients with symptoms of postprandial hypoglycemiaThe sum of many parts: potential mechanisms for improvement in glucose homeostasis after bariatric surgeryEvidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusionSurgical treatment of nonalcoholic fatty liver disease in severely obese patientsMetabolic bariatric surgery and type 2 diabetes mellitus: an endocrinologist's perspective.Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action.Postprandial insulin secretion after gastric bypass surgery: the role of glucagon-like peptide 1.Insulin response to oral stimuli and glucose effectiveness increased in neuroglycopenia following gastric bypassGLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modificationPreserved Insulin Secretory Capacity and Weight Loss Are the Predominant Predictors of Glycemic Control in Patients With Type 2 Diabetes Randomized to Roux-en-Y Gastric BypassImproved Insulin Sensitivity 3 Months After RYGB Surgery Is Associated With Increased Subcutaneous Adipose Tissue AMPK Activity and Decreased Oxidative Stress.Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor AgonistsGastric bypass alters both glucose-dependent and glucose-independent regulation of islet hormone secretion.GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channelEffect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test.Alterations in gastrointestinal, endocrine, and metabolic processes after bariatric Roux-en-Y gastric bypass surgerySuppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4Gastric bypass and banding equally improve insulin sensitivity and β cell functionComparison of Bariatric Surgical Procedures for Diabetes Remission: Efficacy and MechanismsPostprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.Insulinoma After Bariatric Surgery: Diagnostic Dilemma and Therapeutic Approaches.GLP-1 action and glucose tolerance in subjects with remission of type 2 diabetes after gastric bypass surgeryPeripheral, but not central, GLP-1 receptor signaling is required for improvement in glucose tolerance after Roux-en-Y gastric bypass in miceEffects of gastrogastric fistula repair on weight loss and gut hormone levelsVertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like Peptide 1 receptor deficiency.Incretin therapy and islet pathology: a time for caution.Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatmentInactivation of specific β cell transcription factors in type 2 diabetes.
P2860
Q24563430-B2FCC94E-DEFE-4426-A453-0403760CA2E5Q26740015-97712556-400E-4492-AB07-6879158398B7Q26749196-3496E344-0F3E-440B-8778-DDBB2FB2989FQ26995145-544D8DC7-609D-46D4-9681-09E622DFBF54Q27015789-828CCA98-89AB-4361-8A08-DFAB7A812454Q27026687-64589C3B-2BCA-4E60-8DD2-F02A4E2E3810Q27027920-924452E9-0E7B-4F72-8BDD-C45E29AFFB53Q27310949-CCD2A12B-6EAC-4EB6-85F1-73980AA5E400Q28067465-099411A8-E24C-4834-BE09-4270B5235AE9Q28080484-BDECEF3D-CF07-435F-A25C-B4203688E4D8Q28080912-152DC14E-96C3-45C7-9807-1E89461BF47EQ30235568-35085954-30F0-4E15-9005-A5D937CCDBDFQ33682506-C217B933-2782-444C-A705-0A65CF6EE389Q33761529-D50F2AAA-1284-453C-B382-F733BCDCFB43Q33829210-596E293C-48E5-4BC1-8DF4-CA2AEF68252DQ34446294-07975FBA-1FB2-4CF0-98F7-0078564B64B6Q34471033-932742E7-0DAA-404C-B5F5-368945322AD1Q34503739-FC64F3F7-9E3E-43FE-83C4-B86242AFF096Q35180073-885E8AF5-2C42-4DB8-B69A-A3B911D411A5Q35236444-07AFFF16-7AD8-4398-8884-3A738C2E2F0DQ35360690-3FD29529-338A-4B25-9362-7765C8068985Q35973869-ABB179BA-25EE-4E57-BA88-92C00561F34AQ35973905-03CFCC9B-4110-435F-8047-0BB60B706853Q36073461-AE9EFE35-1EF2-41B2-BDF7-E9B1F5FD25DCQ36101563-5E6500CF-0143-4BD8-AF71-71555714E824Q36249759-6A4AC2C6-8BB3-4D6D-8FD0-BB577CDB956DQ36339659-30570934-A0EF-4428-B449-3A77BF435BD0Q36426666-863FFB28-D4D0-4D83-A529-E6963E5A5BFDQ36439654-DAD4B432-1596-40E6-B0F4-0641BC1BD565Q36439877-AEDDC51E-9C5B-4AA8-8A64-8351985695C8Q36479829-E3EF702E-4C68-42E1-9A5E-3542C0F61897Q36520647-775BF800-C890-40C9-B3ED-E1EBB8229701Q36746388-A8B49F44-2308-42AA-9B25-5C734277BDADQ36942165-E053ED04-DACD-4B82-A9AB-8DBAA1CB6256Q36955246-2177B35C-BC8C-4604-9C5B-33D16D15B89FQ36986145-BB9E15AF-FEC3-4D65-83C0-59B529B033CCQ37015063-688D8EC5-CF3A-424A-883E-E4C05DD91440Q37015080-86F856B1-153C-46B1-8FFA-27D1BE7BC007Q37022586-65A21A01-1368-43E7-BDDF-04DB38972631Q37052883-D4491EFD-402E-4595-A500-B48DA9D12637
P2860
Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Gastric bypass surgery enhance ...... al insulin secretion in humans
@ast
Gastric bypass surgery enhance ...... al insulin secretion in humans
@en
type
label
Gastric bypass surgery enhance ...... al insulin secretion in humans
@ast
Gastric bypass surgery enhance ...... al insulin secretion in humans
@en
prefLabel
Gastric bypass surgery enhance ...... al insulin secretion in humans
@ast
Gastric bypass surgery enhance ...... al insulin secretion in humans
@en
P2093
P2860
P356
P1433
P1476
Gastric bypass surgery enhance ...... al insulin secretion in humans
@en
P2093
David A D'Alessio
Marzieh Salehi
Ronald L Prigeon
P2860
P304
P356
10.2337/DB11-0203
P407
P577
2011-09-01T00:00:00Z